LinkedIn
WebsiteIntroduction
SCISPARC LTD (NASDAQ: SPRC) is a specialty clinical-stage pharmaceutical company focused on cannabinoid-based therapies for central nervous system disorders. As of September 25, 2025, its shares traded on the Nasdaq Capital Market at $5.19, reflecting a 35.51% increase for the day, with a trading volume of 4,482,772 shares.
Corporate Structure and Leadership
SCISPARC employs between 11 and 50 staff and is led by a team of experienced executives and scientists. The management team includes:
- Oz Adler, Chief Executive Officer and Chief Financial Officer, with prior experience at Ernst & Young affiliate Kost Forer Gabbay & Kasierer.
- Dr. Dina Zuloff-Shani, Chief Technologies Officer, holding a Ph.D. in Human Biology and Immunology, and previously serving as VP of Development at Macrocure Ltd.
- Mr. Amitay Weiss, Chairman and founder of Amitay Weiss Management, with prior executive experience at Bank Poalei Agudat Israel.
- Mr. Micha Shrem, President, who has over 40 years in financial markets and venture capital and is co-founder of Pitango Venture Capital.
The scientific advisory board is chaired by Professor Raphael Mechoulam, recognized for his contributions to cannabinoid research.
Cannabinoid therapy by Buzzed Buds
Developments and News
- Pipeline Progress: On May 26, 2022, ethics committees in Germany and Israel approved a Phase IIb trial of SCI-110 for Tourette Syndrome at Hannover Medical School and Tel Aviv Sourasky Medical Center.
- Nasdaq Compliance: On January 15, 2025, Nasdaq granted SCISPARC an extension until July 14, 2025, to regain compliance with the $1.00 minimum bid-price requirement.
- Convertible Debentures: In August 2025, investors converted $4.025 million of convertible debentures into 999,528 ordinary shares, raising the total shares outstanding to 1,622,273 as of August 28, 2025. A remaining balance of $175,000 in debentures is still outstanding.
- Merger Proceedings: On September 16, 2025, the Jerusalem District Court granted a stay on merger proceedings with AutoMax Motors Ltd. until September 30, 2025, pending resolution of AutoMax’s ability to meet the closing conditions.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (Sep 25, 2025) | $5.19 (+35.51%) |
| Market Cap | $7.25 M |
| 52-Week Range | $1.75 – $37.59 |
| Revenue (TTM) | $1.31 M |
| Net Income (TTM) | – $6.28 M |
| Total Cash (MRQ) | $2.06 M |
| Debt/Equity (MRQ) | 0.51% |
| Return on Assets (TTM) | – 42.05% |
| Return on Equity (TTM) | – 80.66% |
SCISPARC's trailing twelve-month (TTM) revenue is $1.31 million, with a net loss of $6.28 million, indicative of its ongoing clinical-stage investments. The conversion of convertible debentures in August 2025 strengthened liquidity, while an increase in shares to 1.62 million has raised concerns regarding shareholder dilution. The Nasdaq extension emphasizes the significance of share price management, while uncertainties surrounding the merger with AutoMax present potential operational challenges.
Market Position and Industry Context
Operating in the biotechnology research industry, SCISPARC’s endocannabinoid platform includes four clinical-stage candidates targeting Tourette Syndrome, obstructive sleep apnea, Alzheimer’s disease with agitation, and autism spectrum disorder, along with two preclinical programs for status epilepticus and chronic pain. Competitors include other clinical-stage firms focusing on cannabinoid or CNS therapies. SCISPARC employs an asset-light model that utilizes proprietary formulation technologies aimed at improving bioavailability and safety profiles.
tl;dr
SCISPARC’s stock increased by 35.51% to $5.19 on September 25, 2025, driven by high trading volume. Investors converted $4.025 million of convertible debentures into 999,528 shares, resulting in a total share count of 1.62 million, with $175,000 in debentures remaining. The company has been granted a Nasdaq compliance extension until July 14, 2025, and faces a court-ordered stay on its merger with AutoMax Motors until September 30, 2025. Upcoming developments include finalizing the merger and progressing the Phase IIb SCI-110 trial for Tourette Syndrome.
